1.8500.00% ( 0.000 )
Delay Changed: Oct 23, 16:00:00 (EDT)Current ValuationThe current P/E ratio is -0.13, within the reasonable range, cheaper than 45.45% of the time in the past 1 years, and the industry ranks 11/38, the industry Median -0.87.
-0.132xP/E
--Stock price
-0.132xP/E
Stock price--
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -0.13x
- Typical range
- -0.14x–-0.13x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
013263952
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
HTFLUSHeartFlow | -41.62x | 74.45% | $4.93B |
SDGRUSSchrodinger | -42.31x | 4.47% | $2.51B |
CERTUSCertara | -28.97x | 3,700.00% | $1.86B |
TDOCUSTeladoc | -10.57x | 26.79% | $1.64B |
MDRXUSVeradigm | -- | -- | $808.86M |
SOPHUSSophia Genetics SA | -7.91x | 16.24% | $641.58M |
EVHUSEvolent Health | -1.05x | 85.03% | $532.73M |
CTEVUSClaritev | -1.48x | 15.90% | $406.74M |
AMWLUSAmerican Well | -3.71x | 61.89% | $211.93M |
DHUSDefinitive Healthcare | -1.03x | 21.33% | $162.22M |
HCATUSHealth Catalyst | -0.57x | 4.22% | $114.99M |
LFMDUSLifeMD | -34.76x | 195.82% | $100.98M |
RNLXYUSRENALYTIX PLC SPON ADS EACH REP 50 ORD (POST SPLIT) | -3.15x | -- | $44.68M |
VSEEUSVSee Health | -4.16x | -- | $41.19M |
ONMDUSOneMedNet | -4.22x | -- | $35.57M |
DRIOUSDarioHealth | -2.88x | 60.40% | $20.17M |
AIFFUSFirefly Neuroscience | -1.58x | -- | $14.88M |
ITOCUSiTonic | -1.52x | -- | $13.53M |
BFRGUSBullfrog AI | -1.70x | 41.27% | $10.22M |
SCNXUSScienture | -0.14x | 93.42% | $5.26M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
